ZYMOGENETICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 323
- Market Cap
- -
- Website
- http://www.zymogenetics.com
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 600
- Registration Number
- NCT01001754
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
- Conditions
- Blood Loss, Surgical
- Interventions
- Biological: rThrombin, 1000 IU/mL
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 30
- Registration Number
- NCT00859547
- Locations
- 🇺🇸
Arizona Burn Center, Phoenix, Arizona, United States
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
- Conditions
- Blood Loss, Surgical
- Interventions
- Biological: rThrombin, 1000 IU/mL
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 31
- Registration Number
- NCT00813904
- Locations
- 🇺🇸
Tuscon Orthopaedic Institute, Tuscon, Arizona, United States
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2009-10-07
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 56
- Registration Number
- NCT00565539
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
- Conditions
- Spinal SurgeryVascular Surgery
- Interventions
- Biological: rThrombin
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 234
- Registration Number
- NCT00491608
- Locations
- 🇺🇸
Huntington Memorial Hospital, Pasadena, California, United States
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2009-05-27
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 52
- Registration Number
- NCT00389285
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting
- Conditions
- Surgical Hemostasis
- Interventions
- Biological: rThrombin
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 72
- Registration Number
- NCT00371215
- Locations
- 🇺🇸
Richard M. Fairbanks Burn Center, Wishard Hospital, Indianapolis, Indiana, United States
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 23
- Registration Number
- NCT00347971
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Study of Recombinant Human Thrombin for Bleeding During Surgery
- Conditions
- Surgical Hemostasis
- Interventions
- Biological: rThrombin
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 401
- Registration Number
- NCT00245336
- Locations
- 🇺🇸
Cardio Thoracic Surgeons, P.C., Birmingham, Alabama, United States
🇺🇸Cardio Thoracic Surgeons, P.C., Medical Center East / Baptist Montclair, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
- Conditions
- MelanomaKidney NeoplasmsMetastases
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 43
- Registration Number
- NCT00095108
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States